Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AIDS
MCID: HMN044
MIFTS: 71

Human Immunodeficiency Virus Type 1 (AIDS)

Categories: Cancer diseases, Genetic diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Human Immunodeficiency Virus Type 1

About this section

MalaCards integrated aliases for Human Immunodeficiency Virus Type 1:

Name: Human Immunodeficiency Virus Type 1 56 37
Aids 56 74 54 3 17
Human Immunodeficiency Virus Type 1, Susceptibility to 56 29 6
Hiv/aids 56 42 3
Aids, Delayed/rapid Progression to 56 13
Hiv-1 Viremia, Susceptibility to 56 6
Rapid Progression to Aids from Hiv1 Infection 56
Human Immunodeficiency Virus I Infection 71
Acquired Immunodeficiency Syndrome 71
Hiv1 Infection, Resistance to 56
Hiv Type 1, Susceptibility to 56
Hiv Infection, Resistance to 56
Hiv/aids, Susceptibility to 56
Aids, Rapid Progression to 56
Aids, Slow Progression to 56
Hiv-1, Susceptibility to 56
Hiv-1, Resistance to 56
Aids, Resistance to 56
Hiv1, Resistance to 56
Hiv-Infection/aids 71
Hiv-1 Infection 17
Hiv1 Infection 56
Hiv-1 Viremia 56
Hiv Type 1 56
Hiv-1 56
Hiv1 56

Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases
Anatomical: Immune diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 56 609423
UMLS 71 C0001175 C0276500 C0497169
Sources

Summaries for Human Immunodeficiency Virus Type 1

About this section
MedlinePlus : 42 HIV stands for human immunodeficiency virus. It harms your immune system by destroying the white blood cells that fight infection. This puts you at risk for serious infections and certain cancers. AIDS stands for acquired immunodeficiency syndrome. It is the final stage of infection with HIV. Not everyone with HIV develops AIDS. HIV most often spreads through unprotected sex with a person who has HIV. It may also spread by sharing drug needles or through contact with the blood of a person who has HIV. Women can give it to their babies during pregnancy or childbirth. The first signs of HIV infection may be swollen glands and flu-like symptoms. These may come and go within two to four weeks. Severe symptoms may not appear until months or years later. A blood test can tell if you have HIV infection. Your health care provider can do the test, or you can use a home testing kit. Or to find free testing sites, call the national referral hotline at 1-800-CDC-INFO (1-800-232-4636 in English and en español; 1-888-232-6348 - TTY). There is no cure, but there are many medicines that fight HIV infection and lower the risk of infecting others. People who get early treatment can live with the disease for a long time. Strategies to reduce the risk of HIV infection include not having sex, limiting your number of sexual partners, never sharing needles, and using condoms the right way every time you have sex. People who are at high risk may take HIV prevention medicines.

MalaCards based summary : Human Immunodeficiency Virus Type 1, also known as aids, is related to immune deficiency disease and aspergillosis, and has symptoms including fever and pruritus. An important gene associated with Human Immunodeficiency Virus Type 1 is CXCL12 (C-X-C Motif Chemokine Ligand 12), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pentoxifylline and Sodium Tetradecyl Sulfate have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and brain, and related phenotypes are Increased the percentage of infected cells and hematopoietic system

OMIM : 56 The pathogenesis of HIV infection and the progression from infection to AIDS vary significantly between exposed individuals. Infection occurs after the virus, which has macrophage (M)- and T lymphocyte (T)-tropic strains and more than 12 subtypes, survives an array of nonspecific, nongenetic environmental and host factors. (609423)

CDC : 3 HIV is a virus spread through certain body fluids that attacks the body's immune system, specifically the CD4 cells, often called T cells. Over time, HIV can destroy so many of these cells that the body can't fight off infections and disease. These special cells help the immune system fight off infections. Untreated, HIV reduces the number of CD4 cells (T cells) in the body. This damage to the immune system makes it harder and harder for the body to fight off infections and some other diseases. Opportunistic infections or cancers take advantage of a very weak immune system and signal that the person has AIDS. Learn more about the stages of HIV and how to know whether you have HIV.

Wikipedia : 74 Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) is a spectrum... more...

Sources

Related Diseases for Human Immunodeficiency Virus Type 1

About this section

Diseases related to Human Immunodeficiency Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2964)
# Related Disease Score Top Affiliating Genes
1 immune deficiency disease 33.6 ITIH4 IL10 IFNG CXCL12 CX3CR1 CD9
2 aspergillosis 33.3 TLR3 IL10 IFNG CD209 CCL3
3 acquired immunodeficiency syndrome 33.1 ITIH4 IL4R IL10 IFNG CD9 CCR5
4 human immunodeficiency virus infectious disease 32.3 KIR3DL1 ITIH4 IL10 IFNG CXCL12 CX3CR1
5 viral infectious disease 32.2 TLR3 KIR3DL1 ITIH4 IL10 IFNG CD9
6 stomatitis 32.2 IL10 IFNG BST2
7 encephalitis 32.1 TLR3 ITIH4 IL10 CD209 CCR5 CCL3
8 syphilis 32.1 IFNG HLA-C CD209 CCR5
9 pulmonary tuberculosis 31.9 IL10 IFNG CCL3 CCL2
10 bacterial infectious disease 31.9 TLR3 ITIH4 IL10 IFNG CXCR1 CCL3
11 toxoplasmosis 31.7 IL10 IFNG CCR5 CCL3
12 leprosy 3 31.7 TLR3 IL10 IFNG CD209
13 meningitis 31.7 IL10 IFNG CXCL12 CCL3 CCL2
14 retinal detachment 31.7 IL10 IFNG CXCL12 CCL2
15 cytomegalovirus retinitis 31.7 IL10 IFNG CXCL12 CD9 CCR5 CCR2
16 aids dementia complex 31.7 ITIH4 CXCL12
17 allergic hypersensitivity disease 31.7 IL4R IL10 IFNG CCL3 CCL11
18 schistosomiasis 31.7 IL10 IFNG CCL3 CCL2
19 chickenpox 31.7 TLR3 IL10 IFNG
20 hepatitis c 31.6 TLR3 IL10 IFNG CCR5
21 pelvic inflammatory disease 31.6 IFNG CXCL12 CCL2
22 demyelinating disease 31.5 IL10 IFNG CCL3 CCL2
23 herpes zoster 31.5 IL10 IFNG CCR5
24 leishmaniasis 31.5 IL10 IFNG CCR5 CCL2
25 aseptic meningitis 31.5 IL10 IFNG CCL3
26 lung disease 31.5 IL10 IFNG CXCR1 CCR5 CCL3 CCL2
27 tropical spastic paraparesis 31.4 IL10 IFNG CCL3
28 invasive aspergillosis 31.4 IL4R IL10 IFNG
29 graft-versus-host disease 31.4 IL10 IFNG HLA-C
30 severe acute respiratory syndrome 31.4 IL10 IFNG CD209 CCL3 CCL2
31 rubella 31.4 TLR3 IL10 IFNG HLA-C
32 sarcoidosis 1 31.4 IFNG CCR5 CCL3 CCL2 CCL11
33 hepatitis a 31.4 TLR3 IL10 IFNG
34 leptospirosis 31.3 IL10 IFNG CCL2
35 chlamydia 31.3 IL10 IFNG CCL2
36 proteasome-associated autoinflammatory syndrome 1 31.3 TLR3 IL10 IFNG CCL3 CCL2 CCL11
37 pulmonary disease, chronic obstructive 31.2 IL10 CXCR1 CCR5 CCL3 CCL2 CCL11
38 thrombocytopenia 31.2 IL10 IFNG CXCL12 CD209 CCL2
39 salmonellosis 31.2 TLR3 IL10 IFNG
40 pneumonia 31.2 TLR3 IL10 IFNG CCL3 CCL2 CCL11
41 myocarditis 31.2 TLR3 IL10 IFNG CCL3 CCL2
42 myeloma, multiple 31.2 TLR3 IL10 IFNG CXCL12 CCL3 CCL2
43 lymphadenitis 31.1 IL10 IFNG CD209
44 mumps 31.1 TLR3 IL10 IFNG
45 contact dermatitis 31.1 IL10 IFNG CCL2
46 gingivitis 31.1 IL10 IFNG CCL2
47 rheumatoid arthritis 31.1 IL10 IFNG CXCL12 CX3CR1 CCR5 CCR2
48 polyradiculoneuropathy 31.1 IL10 IFNG CXCL12
49 htlv-1 associated myelopathy/tropical spastic paraparesis 31.1 CXCR1 CX3CR1
50 systemic lupus erythematosus 31.1 TLR3 IL10 IFNG CXCL12 CX3CR1 CCR5

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Type 1:



Diseases related to Human Immunodeficiency Virus Type 1
Sources

Symptoms & Phenotypes for Human Immunodeficiency Virus Type 1

About this section

Clinical features from OMIM:

609423

UMLS symptoms related to Human Immunodeficiency Virus Type 1:


fever, pruritus

GenomeRNAi Phenotypes related to Human Immunodeficiency Virus Type 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased the percentage of infected cells GR00402-S-1 8.62 IL10 TLR3

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Type 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CCL11 CCR2 CCR5 CD9 CX3CR1 CXCL12
2 immune system MP:0005387 9.9 CCL11 CCL2 CCR2 CCR5 CD9 CX3CR1
3 liver/biliary system MP:0005370 9.5 CCR2 CCR5 CXCL12 IFNG IL10 IL4R
4 neoplasm MP:0002006 9.17 CCR2 CCR5 CD9 IFNG IL10 ITIH4
Sources

Drugs & Therapeutics for Human Immunodeficiency Virus Type 1

About this section

Drugs for Human Immunodeficiency Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 997)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
2
Sodium Tetradecyl Sulfate Approved, Investigational Phase 4 1191-50-0, 139-88-8 5248 14492
3
Sodium sulfate Approved, Vet_approved Phase 4 7757-82-6
4
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
5
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
6
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
7
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
8
leucovorin Approved Phase 4 58-05-9 6006 143
9
Sulfamethoxazole Approved Phase 4 723-46-6 5329
10
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
11
Acyclovir Approved Phase 4 59277-89-3 2022
12
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
13
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
14
Atovaquone Approved Phase 4 95233-18-4 74989
15
Zalcitabine Approved, Investigational Phase 4 7481-89-2 24066
16
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
17
Fosamprenavir Approved Phase 4 226700-79-4 131536
18
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
19
Megestrol acetate Approved, Investigational, Vet_approved Phase 4 595-33-5 11683
20
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
21
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
22
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
23
Ledipasvir Approved Phase 4 1256388-51-8 67505836
24
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
26
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
27
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
28
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
29
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
30
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
31
Acetaminophen Approved Phase 4 103-90-2 1983
32
Losartan Approved Phase 4 114798-26-4 3961
33
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
34
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
35
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
36
Copper Approved, Investigational Phase 4 7440-50-8 27099
37
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
38
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
39
Ferrous fumarate Approved Phase 4 141-01-5
40
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
41
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
42
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
43
carbamide peroxide Approved Phase 4 124-43-6
44
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
45
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
46
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
47
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
48
Desipramine Approved, Investigational Phase 4 50-47-5 2995
49
Oxandrolone Approved, Investigational Phase 4 53-39-4 5878
50
Proguanil Approved Phase 4 500-92-5 4923

Interventional clinical trials:

(show top 50) (show all 6482)
# Name Status NCT ID Phase Drugs
1 Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study Unknown status NCT01049685 Phase 4 First-line Antiretroviral Therapy
2 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
3 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
4 Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B Unknown status NCT03120494 Phase 4 Emtricitabine and Tenofovir
5 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir（RAL）in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
6 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
7 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
8 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
9 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
10 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
11 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4 Maraviroc
12 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adults Unknown status NCT01017172 Phase 4
13 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
14 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
15 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
16 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
17 Systematic Empirical vs. Test-guided Anti-tuberculosis Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating Antiretroviral Therapy With CD4 Cell Counts <100/mm3: the STATIS Randomized Controlled Trial Unknown status NCT02057796 Phase 4 ART (Atripla, Truvada, Efavirenz, Combivir);Rifampin, isoniazid, pyrazinamide, ethambutol
18 A Phase IV Open-label, Multi-centre, Randomised, Dual-arm, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Dolutegravir Unknown status NCT02285374 Phase 4 Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
19 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
20 A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
21 Is Dual Therapy as Effective as Triple Therapy Regarding CD4+/CD8+ Ratio Recovery and Improvement of Immune Activation and Inflammation in HIV-infected Patients With Consistent Plasma Viral Load Suppression (Tridual) Unknown status NCT03447873 Phase 4 Continue with triple therapy;Switch to DTG + 3TC;Switch to DRV/cobicistat + 3TC
22 An Open, Single-Arm, Multi-Center, Phase IV Pilot Study of Treatment of Antiretroviral Naive HIV-1 Infected Patients With Tenofovir Disoproxil Fumarate in Combination With Emtricitabine and Zidovudine Unknown status NCT00199121 Phase 4 Zidovudine (drug)
23 A Pilot Study of Highly Active Antiretroviral Therapy Using Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Antiretroviral Naive HIV-Infected Subjects Unknown status NCT00740064 Phase 4 Raltegravir and Abacavir/Lamivudine
24 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
25 A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
26 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
27 A Phase 4, Single Arm, Open Label, Pilot Study of Maraviroc (Celsentri) in Combination With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients. Unknown status NCT01013987 Phase 4 maraviroc;Raltegravir;Darunavir/ritonavir
28 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
29 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
30 HIV Pre-Exposure Prophylaxis Priming of Immune Effectors Unknown status NCT02593409 Phase 4 TDF/FTC
31 Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS) Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
32 A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
33 Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860 Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
34 A Phase IV, Multicentre Randomized Prospective Open Label Study to Evaluate Whether Switching From Current cART to Triumeq in Addition to Adherence Support Will Enhance Virologic Control and Adherence in Vulnerable Populations Relative to Adherence Support Alone Unknown status NCT02354053 Phase 4 Switch to Triumeq
35 A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT) Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
36 Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C Unknown status NCT01147107 Phase 4 Raltegravir;Efavirenz
37 The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness Unknown status NCT01264510 Phase 4
38 Maraviroc Abacavir STudy - Effect on Endothelial Recovery Unknown status NCT01389063 Phase 4 Maraviroc
39 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
40 A Pilot Randomized, Open Label Study to Evaluate Efficacy and Safety of the Combination of RAL+ATV/r in Comparison With TDF/FTC+ATV/r in HIV Infected Patients, Who Failed an Initial NNRTI Containing Regimen Unknown status NCT01829802 Phase 4 Ritonavir boosted Atazanavir;Raltegravir;TDF/FTC (or 3TC)
41 Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations Unknown status NCT01347294 Phase 4 Bleomycin;Fibrovein;Bleomycin + Fibrovein
42 Treating HIV-infected Elite Controllers as a Model of HIV Remission Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
43 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
44 Curing HCV in Incarcerated Patients Unknown status NCT03018353 Phase 4 Patients receiving Sof/Vel (Epclusa) and Navigation services
45 Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care Unknown status NCT01195493 Phase 4
46 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
47 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled，Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
48 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
49 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
50 Open Label, Nonrandomized Clinical Trial of Safety and Tolerability of Enfuviritide (Fuzeon®, HIV Fusion Inhibitor) in Patients With Advanced HIV1 Infection Completed NCT02569502 Phase 4 enfuvirtide

Search NIH Clinical Center for Human Immunodeficiency Virus Type 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


abacavir
abacavir sulfate
Amprenavir
Delavirdine
Delavirdine Mesylate
Didanosine
efavirenz
enfuvirtide
Immunoglobulins, Intravenous
Indinavir
Indinavir Sulfate
Lamivudine
lopinavir
Nelfinavir
Nelfinavir Mesylate
Nevirapine
Ritonavir
Saquinavir
saquinavir mesylate
Stavudine
Tenofovir
tenofovir alafenamide fumarate
Tenofovir disoproxil fumarate
Zalcitabine
Zidovudine

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Human Immunodeficiency Virus Type 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Human Immunodeficiency Virus Type 1:
AGS-004, electroporated mature dendritic cells for HIV
Embryonic/Adult Cultured Cells Related to Human Immunodeficiency Virus Type 1:
Maturated and electroporated dendritic cells PMIDs: 20636001
Sources

Genetic Tests for Human Immunodeficiency Virus Type 1

About this section

Genetic tests related to Human Immunodeficiency Virus Type 1:

# Genetic test Affiliating Genes
1 Human Immunodeficiency Virus Type 1, Susceptibility to 29 CCL11 CCL2 CCL3 CCL3L1 CD209 CX3CR1 CXCL12 CXCR1 HLA-C IFNG IL10 IL4R KIR3DL1 TLR3
Sources

Anatomical Context for Human Immunodeficiency Virus Type 1

About this section

MalaCards organs/tissues related to Human Immunodeficiency Virus Type 1:

40
Testes, T Cells, Brain, Bone, Breast, Monocytes, Liver
Sources

Publications for Human Immunodeficiency Virus Type 1

About this section

Articles related to Human Immunodeficiency Virus Type 1:

(show top 50) (show all 50220)
# Title Authors PMID Year
1
Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) 6 56 61 54
9430590 1998
2
Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. 61 54 6 56
9252328 1997
3
Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. 6 56 61
15564514 2004
4
A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. 6 56
22174453 2012
5
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. 6 56
19935663 2009
6
MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. 6 56
14571188 2003
7
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. 6 56
11121048 2000
8
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. 56 6
8756719 1996
9
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. 6 56
8751444 1996
10
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. 56 54 61
17243065 2007
11
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. 61 56 54
12134147 2002
12
Genetic acceleration of AIDS progression by a promoter variant of CCR5. 54 61 56
9836644 1998
13
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. 56 54 61
8791590 1996
14
Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. 56 61
22190037 2011
15
The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. 56 61
20871604 2010
16
Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. 56 61
17906637 2007
17
A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients. 56 54
17360650 2007
18
Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. 56 61
17306567 2007
19
Structural definition of a conserved neutralization epitope on HIV-1 gp120. 56 61
17301785 2007
20
The case for selection at CCR5-Delta32. 6 54
16248677 2005
21
Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. 54 56
16189667 2005
22
Influence of host genetic variation on susceptibility to HIV type 1 infection. 56 61
15630678 2005
23
Human genes that limit AIDS. 61 56
15167933 2004
24
Modulating influence on HIV/AIDS by interacting RANTES gene variants. 61 56
12114533 2002
25
A homologous naturally occurring mutation in Duffy and CCR5 leading to reduced receptor expression. 54 6
11369664 2001
26
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. 56 61
11386265 2001
27
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. 56 61
10073943 1999
28
CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). 54 6
9742978 1998
29
Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users. 6 54
9600249 1998
30
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. 54 6
9132277 1997
31
A COVID-19 conference at AIDS 2020: Virtual. 42 61
32359401 2020
32
Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. 56
29302013 2018
33
SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. 56
26416733 2015
34
HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. 56
26416734 2015
35
HIV Blocks Interferon Induction in Human Dendritic Cells and Macrophages by Dysregulation of TBK1. 56
25855743 2015
36
TOE1 is an inhibitor of HIV-1 replication with cell-penetrating capability. 56
26056259 2015
37
PQBP1 Is a Proximal Sensor of the cGAS-Dependent Innate Response to HIV-1. 56
26046437 2015
38
Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. 56
22988032 2012
39
T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. 56
22190036 2011
40
Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. 6
21911422 2011
41
Genetic diversity at endoplasmic reticulum aminopeptidases is maintained by balancing selection and is associated with natural resistance to HIV-1 infection. 56
20843824 2010
42
Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. 56
20445539 2010
43
Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4+ T lymphocytes. 56
20173753 2010
44
The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry. 56
19620399 2009
45
Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B. 6
19017985 2008
46
Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. 56
18806803 2008
47
Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. 56
18621010 2008
48
Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. 56
18562290 2008
49
Identification of host proteins required for HIV infection through a functional genomic screen. 56
18187620 2008
50
A whole-genome association study of major determinants for host control of HIV-1. 56
17641165 2007
Sources

Variations for Human Immunodeficiency Virus Type 1

About this section

ClinVar genetic disease variations for Human Immunodeficiency Virus Type 1:

6 (show all 15) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CCR5 NM_000579.3(CCR5):c.303T>A (p.Cys101Ter)SNV protective 8188 rs1800560 3:46414696-46414696 3:46373205-46373205
2 CCR5 NM_000579.3(CCR5):c.-301+246A>GSNV protective 8189 rs1799987 3:46411935-46411935 3:46370444-46370444
3 CCR5 NM_000579.3(CCR5):c.180G>T (p.Arg60Ser)SNV protective 8191 rs1800940 3:46414573-46414573 3:46373082-46373082
4 CCR2 NM_001123041.2(CCR2):c.190G>A (p.Val64Ile)SNV protective 8267 rs1799864 3:46399208-46399208 3:46357717-46357717
5 CCL11 CCL11, -1385G-ASNV protective 8367
6 CXCL12 NM_199168.4(CXCL12):c.*531G>ASNV protective 8762 rs387906400 10:44873550-44873550 10:44378102-44378102
7 CCL2 CCL2, -2136A-TSNV protective 14205
8 CCL2 CCL2, 767C-GSNV protective 14206
9 CD209 CD209, -336A-GSNV protective,risk factor 5408
10 IL10 NM_153758.3(IL19):c.-35+1984T>GSNV protective,risk factor 16873 rs1800872 1:206946407-206946407 1:206773062-206773062
11 HLA-C NC_000006.12:g.31306603T>CSNV risk factor 14907 rs9264942 6:31274380-31274380 6:31306603-31306603
12 IL4R NM_000418.4(IL4R):c.1160C>T (p.Ser387Leu)SNV Conflicting interpretations of pathogenicity 626118 rs6413500 16:27373833-27373833 16:27362512-27362512
13 IL4R NM_000418.4(IL4R):c.1774G>T (p.Val592Leu)SNV Uncertain significance 827982 16:27374447-27374447 16:27363126-27363126
14 TLR3 NM_003265.3(TLR3):c.1234C>T (p.Leu412Phe)SNV Benign/Likely benign 41472 rs3775291 4:187004074-187004074 4:186082920-186082920
15 CCR5 NM_000579.3(CCR5):c.554_585del (p.Ser185fs)deletion Benign 8184 rs333 3:46414944-46414975 3:46373453-46373484

Copy number variations for Human Immunodeficiency Virus Type 1 from CNVD:

7 (show all 23)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13736 1 1 247249719 Copy number HIV/AIDS
2 74031 13 1 114142980 Copy number HIV/AIDS
3 107129 17 1225928 31649829 Copy number CCL3L3 HIV/AIDS
4 107135 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
5 107136 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
6 107137 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
7 107145 17 1225928 31649843 Segmental duplications CCL3L1 HIV/AIDS
8 107159 17 1242109 31665953 Copy number CCL4L2 HIV/AIDS
9 110228 17 31562580 31665959 Copy number CCL4L1 HIV/AIDS
10 110279 17 31800000 38100000 Copy number CCL3L1 HIV/AIDS
11 110285 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
12 110286 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
13 110848 17 34522267 34625730 Copy number CCL3L1 HIV/AIDS
14 111275 17 35400000 35600000 Copy number CCL3L1 HIV/AIDS
15 112166 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
16 112167 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
17 112170 17 38100000 38400000 Loss CCL3L1 HIV/AIDS
18 179925 4 1 191273063 Copy number HIV/AIDS
19 209403 6 2614953 31491069 Copy number MICA HIV/AIDS
20 211349 6 32593131 32665540 Copy number HLA-DRB5 HIV/AIDS
21 212276 6 3674895 32665540 Copy number HLA-DRB1 HIV/AIDS
22 212425 6 3795995 32719407 Copy number HLA-DQA1 HIV/AIDS
23 212441 6 3813334 32742444 Copy number HLA-DQB1 HIV/AIDS
Sources

Expression for Human Immunodeficiency Virus Type 1

About this section
Search GEO for disease gene expression data for Human Immunodeficiency Virus Type 1.
Sources

Pathways for Human Immunodeficiency Virus Type 1

About this section

Pathways related to Human Immunodeficiency Virus Type 1 according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1